What today’s biotech leaders are teaching us

In the second season of Parexel Biotech’s podcast, Clinical Trialblazers, we’ve continued to sit down with today’s biotech visionaries to talk about the pivotal moments that have shaped their careers, the lessons they have learned throughout their journeys, and the advice they would give to aspiring innovators in the industry. 

This season opened with two insightful conversations reflecting the realities of building and advancing biotech programs today. In episode one, host Alberto Grignolo sat down with Paul Garofolo, Co-Founder and CEO of Locus Biosciences, who talked about capital discipline, execution, and what it takes to lead through uncertainty. The second episode featured Dr. Allison Jeynes, CEO of Nefro Avillion Clinical Development, who reflected on her career journey from clinician to biotech leader, and on the clinical development model that she adopted and has delivered exceptional success.

While their perspectives come from different vantage points, both reveal a shift in what defines success in biotech—where execution, capital discipline, and leadership under pressure are as crucial as the underlying science. In these early conversations of Season 2 of Clinical Trialblazers, several key themes stand out.

Selection is critical, but execution determines outcomes

In the conversations with both Paul and Allison, one point was clear: scientific promise alone does not determine success.

Asset selection of course is foundational. Allison spoke to the rigor required to evaluate large numbers of opportunities and identify those that have a credible path forward. But what follows that decision is where outcomes begin to diverge and success is shaped by execution—how effectively a scientific asset is translated into a fully developed therapeutic—through study design, endpoint selection, site performance, and the quality of data generated. As Allison noted, “great assets fail either because of poor execution or the wrong study design, so it's about making sure that the science is sound around it, but that you also have the strongest team that you can have experience-wise and focused to ensure you have quality data coming out the other end.” 

This suggests a subtle but important shift in emphasis. In practice, organizations often invest heavily in getting to the “right” asset. The greater challenge, however, is maintaining discipline after that decision has been made—when complexity increases and huge variability is introduced.

Constraint forces clarity

Both Paul and Allison also highlighted the idea that time and capital are not passive variables. 

Paul spoke candidly about the difference between leading during favorable financial conditions and leading when capital is limited, noting, “It's easy to be a leader when money's flowing in. It's really hard to be a leader when money gets tight and teams get impatient and partners walk away.”

He discussed the set of operational choices required to keep programs advancing under those constraints, starting with how work is structured. Breaking programs into smaller, decision-centered steps enables earlier data readouts and reduces the risk that comes with extended timelines. In parallel, this requires making deliberate trade-offs to preserve momentum when resources are limited. 

Under these conditions, leadership requires a careful balance of prioritization and breadth. With limited resources, progress depends on concentrating effort on what will most directly advance the program, while making trade-offs informed by clinical, operational, and financial considerations.

Constraint, in practice, changes how organizations operate and forces clarity around what matters most to move a program forward. For drug development leaders, this means that constraints determine how programs are funded, sequenced, and sustained.

People-centered decisions shape execution

The importance of people emerged as a theme as well, particularly from Allison’s perspective, but with a twist.

Effective leadership can and should connect both the teams executing the work and the patients participating in clinical trials. Allison spoke to the need for empathy and a company culture that supports high performance without losing sight of the individual experience of both employees and patients, noting, “It's easy to be friends with people you know, in the good times and go to their party, but it's the people that you would call in the middle of the night when something went wrong. And really I do try and create that culture that really does allow people to feel supported within their role and within their job.” It’s this type of powerful leadership that enables teams to operate with a balance of support and accountability, and with a focus on clinical study patients. 

Paul reinforced this, noting that particularly in smaller organizations, purpose can become a critical performance driver as teams are often asked to take on high-impact work earlier in their careers. In these cases, motivation is closely tied to a clear understanding of the problem being solved and its potential impact on patients as he noted, “You’re working on something that could potentially change the world, and you're getting an opportunity to work on complex activities that nobody else would ever dream of giving you in a larger organization.”

Across both conversations, the takeaway is that people, and importantly patients, are not a secondary consideration in drug development. How teams are led and how patients experience a study directly influence how effectively a program is executed.

What this signals for biotech leaders

Taken together, these conversations point to how a good measure of success is determined after the initial strategy is set—through execution, trade-offs informed by constraints, and how teams are led through uncertainty.

The ability to make decisions with incomplete data and to sustain momentum through challenging periods increasingly differentiates successful organizations.

We look forward to continuing these conversations throughout Season 2 of Clinical Trialblazers and exploring how other biotech leaders are navigating these dynamics in practice.

Tune in to the full Clinical Trialblazers episodes with Paul Garofolo, Co-Founder and CEO of Locus Biosciences, and Dr. Allison Jeynes, CEO of Nefro Avillion.
 

Explore more episodes